September 01, 2025 a 12:39 pm
JNJ: Analysts Ratings - Johnson & Johnson
Johnson & Johnson possesses a diversified portfolio in the healthcare sector, providing resilience against market volatility. Recent analyst ratings show a mixed sentiment with an inclination towards holding the stock, reflecting the company’s stable but non-aggressive growth trajectory. The ongoing commitment to R&D and strong product lineup offer growth potential, though competition in the pharmaceutical and consumer health segments remains fierce.
Historical Stock Grades
Analysis of the latest analyst ratings data for Johnson & Johnson indicates a prevailing sentiment of caution, reflecting in the significant number of Hold recommendations. The company has captured the attention of analysts, partly due to its longstanding presence in the healthcare industry and the broadness of its product segments.
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 2 | |
| Buy | 8 | |
| Hold | 14 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
Over recent months, the total number of analyst ratings for JNJ has slightly increased, with notable stability in the Hold category, which underscores market watchers’ current prudent viewpoint. Key observations include:
- The number of Strong Buy ratings has decreased from 4 to 2, showing a more conservative outlook on potential significant uptrend opportunities.
- Hold ratings have remained relatively constant, indicating a steady market perspective on the stock's future prospects.
- A decrease in Buy recommendations shows a slight restraint among analysts, possibly attributed to increasing market competition.
Percentage Trends
The percentage distribution of the analyst ratings reflects a notable predominance of Hold evaluations, illustrating a cautious outlook. Recent developments in rating percentages are highlighted by the ongoing shift:
- The proportion of Strong Buy ratings reduced from 22.2% to 11.1%, hinting at diminished immediate upside potential as perceived by analysts.
- The stability in Hold ratings around the 50% mark suggests continued confidence in JNJ's consistency amidst changing market conditions.
- Buy recommendations have waxed and waned slightly, now representing 44.4% of sentiments, indicative of fluctuating short-term confidence.
Latest Analyst Recommendations
A review of the most recent analysis provides insight into JNJ's perceived valuation and prospects. Consistency in recommendations points to an evaluative steadiness among industry experts:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-21 | Buy | Buy | Citigroup |
| 2025-07-17 | Equal Weight | Equal Weight | Barclays |
| 2025-07-17 | Buy | Buy | UBS |
| 2025-07-17 | Neutral | Neutral | B of A Securities |
| 2025-07-17 | Outperform | Outperform | RBC Capital |
Analyst Recommendations with Change of Opinion
Observing shifts in analyst recommendations reveals dynamic sentiment fluctuations. Such changes are significant indicators of shifting confidence levels in JNJ's performance:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-13 | Market Perform | Outperform | Leerink Partners |
| 2025-04-09 | Buy | Neutral | Goldman Sachs |
| 2024-07-23 | Neutral | Outperform | Daiwa Capital |
| 2024-04-18 | Buy | Hold | HSBC |
| 2023-12-13 | Equal Weight | Overweight | Wells Fargo |
Interpretation
The current analyst sentiment towards Johnson & Johnson's stock indicates a more reserved outlook, with a noticeable tilt towards Hold rather than aggressive Buy or Sell positions. There is a balanced stable perception of company performance, with limited anticipation of major fluctuations in its market value in the short term. The adjustments in recommendations suggest limited uncertainty yet highlight external competitive pressures. This overall sentiment reflects modest market confidence, leaving room for cautious optimism as JNJ proceeds in strategic growth initiatives.
Conclusion
Johnson & Johnson remains a reliable choice for risk-averse investors due to its enduring market presence and diverse healthcare portfolio. Despite competitive pressures, its consistent growth strategy and innovation in healthcare products continue to assure stakeholders of its robust long-term outlook. However, the prevailing Hold sentiment among analysts suggests a tempered enthusiasm and highlights the company's need to innovate to maintain market leadership. While risks from market dynamics persist, JNJ's seasoned operational strategy and brand strength suggest a stable, albeit modest, growth trajectory ahead.